ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,0724
0,00%
Bitcoin
63.177,56
0,46%
Brent Oil
82,765
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Rocket Pharmaceuticals Inc (RCKT)

  7. Rocket Pharmaceuticals Inc (RCKT) Notícias

RCKT

Rocket Pharmaceuticals (RCKT)

Rocket Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RCKT
DataHoraFonteTítuloCódigoCompanhia
02/04/202407:00Business WireRocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi AnemiaNASDAQ:RCKTRocket Pharmaceuticals Inc
26/03/202417:01Business WireRocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership TeamNASDAQ:RCKTRocket Pharmaceuticals Inc
04/03/202420:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
29/02/202417:54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
26/02/202418:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RCKTRocket Pharmaceuticals Inc
26/02/202418:01Business WireRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ProgressNASDAQ:RCKTRocket Pharmaceuticals Inc
16/02/202419:28Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:RCKTRocket Pharmaceuticals Inc
13/02/202409:00Business WireRocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)NASDAQ:RCKTRocket Pharmaceuticals Inc
29/01/202417:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RCKTRocket Pharmaceuticals Inc
02/01/202418:01Business WireRocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RCKTRocket Pharmaceuticals Inc
12/12/202322:42Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
12/12/202309:00Business WireRocket Pharmaceuticals Appoints R. Keith Woods to Board of DirectorsNASDAQ:RCKTRocket Pharmaceuticals Inc
07/11/202318:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RCKTRocket Pharmaceuticals Inc
06/11/202318:04Business WireRocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent ProgressNASDAQ:RCKTRocket Pharmaceuticals Inc
20/10/202319:37Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:RCKTRocket Pharmaceuticals Inc
19/10/202308:00Business WireRocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)NASDAQ:RCKTRocket Pharmaceuticals Inc
02/10/202308:00Business WireRocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)NASDAQ:RCKTRocket Pharmaceuticals Inc
26/09/202317:01Business WireRocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines ConferenceNASDAQ:RCKTRocket Pharmaceuticals Inc
20/09/202317:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RCKTRocket Pharmaceuticals Inc
19/09/202317:15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:RCKTRocket Pharmaceuticals Inc
13/09/202308:37IH Market NewsWednesday’s Wall Street Highlights: Apple, Xpeng, GoDaddy, BP, UBS, Nike, and moreNASDAQ:RCKTRocket Pharmaceuticals Inc
13/09/202301:01Business WireRocket Pharmaceuticals Announces Pricing of Public Offering of Common StockNASDAQ:RCKTRocket Pharmaceuticals Inc
12/09/202318:28Dow Jones NewsRocket Pharmaceuticals Stock Surges 34% on FDA Alignment for Danon Disease TreatmentNASDAQ:RCKTRocket Pharmaceuticals Inc
12/09/202317:55Dow Jones NewsRocket Pharmaceuticals Reaches FDA Alignment in Danon Heart Disease Treatment TrialNASDAQ:RCKTRocket Pharmaceuticals Inc
12/09/202317:02Business WireRocket Pharmaceuticals Announces Proposed Public Offering of Common StockNASDAQ:RCKTRocket Pharmaceuticals Inc
12/09/202317:01Business WireRocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon DiseaseNASDAQ:RCKTRocket Pharmaceuticals Inc
06/09/202317:05Business WireRocket Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:RCKTRocket Pharmaceuticals Inc
10/08/202308:00Business WireRocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent ProgressNASDAQ:RCKTRocket Pharmaceuticals Inc
26/06/202320:49Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RCKTRocket Pharmaceuticals Inc
23/06/202317:28Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RCKTRocket Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RCKT

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HOOT4
HOTEIS OTHON PN
BOV
PRIO3
PETRORIO ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados